PRAXIS PRECISION MEDICINES, INC. Operating Expenses
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Operating Expenses of $96.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. operating expenses for the quarter ending 2026-06-30 was $96.90M, a 27.39% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. operating expenses for the quarter ending 2026-03-31 was $105.86M, a 41.66% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. operating expenses for the quarter ending 2025-12-31 was $97.04M, a 35.88% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. operating expenses for the quarter ending 2025-09-30 was $78.36M, a 37.14% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. operating expenses for fiscal 2025 was $326.20M, a 56.29% increase from fiscal 2024.
- PRAXIS PRECISION MEDICINES, INC. operating expenses for fiscal 2024 was $208.72M, a 62.02% increase from fiscal 2023.
- PRAXIS PRECISION MEDICINES, INC. operating expenses for fiscal 2023 was $128.82M, a 40.08% decline from fiscal 2022.
- PRAXIS PRECISION MEDICINES, INC. operating expenses for fiscal 2022 was $214.99M, a 28.48% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $96.90M 10-Q · filed 2026-08-06 | $202.76M 10-Q · filed 2026-08-06 | $299.81M derived: sum of 3 quarters · filed 2026-08-06 | $378.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $105.86M 10-Q · filed 2026-05-07 | $202.90M derived: sum of 2 quarters · filed 2026-05-07 | $281.26M derived: sum of 3 quarters · filed 2026-05-07 | $357.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $97.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $175.40M derived: sum of 2 quarters · filed 2026-02-19 | $251.47M derived: sum of 3 quarters · filed 2026-08-06 | $326.20M 10-K · filed 2026-02-19 |
| 2025-09-30 | $78.36M 10-Q · filed 2025-11-05 | $154.43M derived: sum of 2 quarters · filed 2026-08-06 | $229.15M 10-Q · filed 2025-11-05 | $300.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $76.07M 10-Q · filed 2026-08-06 | $150.79M 10-Q · filed 2026-08-06 | $222.21M derived: sum of 3 quarters · filed 2026-08-06 | $279.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $74.73M 10-Q · filed 2026-05-07 | $146.15M derived: sum of 2 quarters · filed 2026-05-07 | $203.28M derived: sum of 3 quarters · filed 2026-05-07 | $241.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $71.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $128.56M derived: sum of 2 quarters · filed 2026-02-19 | $166.40M derived: sum of 3 quarters · filed 2026-02-19 | $208.72M 10-K · filed 2026-02-19 |
| 2024-09-30 | $57.14M 10-Q · filed 2025-11-05 | $94.98M derived: sum of 2 quarters · filed 2025-11-05 | $137.30M 10-Q · filed 2025-11-05 | $165.62M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $37.84M 10-Q · filed 2025-08-04 | $80.16M 10-Q · filed 2025-08-04 | $108.48M derived: sum of 3 quarters · filed 2026-02-19 | $134.47M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $42.32M 10-Q · filed 2025-05-02 | $70.64M derived: sum of 2 quarters · filed 2026-02-19 | $96.62M derived: sum of 3 quarters · filed 2026-02-19 | $132.36M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $28.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $54.30M derived: sum of 2 quarters · filed 2026-02-19 | $90.05M derived: sum of 3 quarters · filed 2026-02-19 | $128.82M 10-K · filed 2026-02-19 |
| 2023-09-30 | $25.98M 10-Q · filed 2024-11-06 | $61.73M derived: sum of 2 quarters · filed 2024-11-06 | $100.50M 10-Q · filed 2024-11-06 | $141.95M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $35.74M 10-Q · filed 2024-08-13 | $74.52M 10-Q · filed 2024-08-13 | $115.97M derived: sum of 3 quarters · filed 2024-08-13 | $160.26M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $38.77M 10-Q · filed 2024-05-13 | $80.23M derived: sum of 2 quarters · filed 2024-05-13 | $124.52M derived: sum of 3 quarters · filed 2024-05-13 | $184.91M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $41.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $85.74M derived: sum of 2 quarters · filed 2024-03-05 | $146.14M derived: sum of 3 quarters · filed 2024-03-05 | $214.99M 10-K · filed 2024-03-05 |
| 2022-09-30 | $44.29M 10-Q · filed 2023-11-07 | $104.68M derived: sum of 2 quarters · filed 2023-11-07 | $173.53M 10-Q · filed 2023-11-07 | $232.19M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $60.39M 10-Q · filed 2023-08-09 | $129.24M 10-Q · filed 2023-08-09 | $187.90M derived: sum of 3 quarters · filed 2023-08-09 | $232.67M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $68.85M 10-Q · filed 2023-05-11 | $127.51M derived: sum of 2 quarters · filed 2023-05-11 | $172.28M derived: sum of 3 quarters · filed 2023-05-11 | $208.76M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $58.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $103.43M derived: sum of 2 quarters · filed 2023-02-07 | $139.91M derived: sum of 3 quarters · filed 2023-02-07 | $167.33M 10-K · filed 2023-02-07 |
| 2021-09-30 | $44.77M 10-Q · filed 2022-11-09 | $81.26M derived: sum of 2 quarters · filed 2022-11-09 | $108.67M 10-Q · filed 2022-11-09 | $134.39M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $36.48M 10-Q · filed 2022-08-08 | $63.90M 10-Q · filed 2022-08-08 | $89.61M derived: sum of 3 quarters · filed 2022-08-08 | $105.83M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $27.42M 10-Q · filed 2022-05-09 | $53.13M derived: sum of 2 quarters · filed 2022-05-09 | $69.35M derived: sum of 3 quarters · filed 2022-05-09 | $80.92M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $25.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $41.93M derived: sum of 2 quarters · filed 2022-02-28 | $53.50M derived: sum of 3 quarters · filed 2022-02-28 | $61.97M 10-K · filed 2022-02-28 |
| 2020-09-30 | $16.22M 10-Q · filed 2021-11-03 | $27.79M derived: sum of 2 quarters · filed 2021-11-03 | $36.26M 10-Q · filed 2021-11-03 | $43.75M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $11.57M 10-Q · filed 2021-08-16 | $20.04M 10-Q · filed 2021-08-16 | $27.53M derived: sum of 3 quarters · filed 2021-08-16 | $38.19M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $8.47M 10-Q · filed 2021-05-11 | $15.96M derived: sum of 2 quarters · filed 2021-05-11 | $26.62M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $7.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $18.15M derived: sum of 2 quarters · filed 2021-03-17 | $35.79M 10-K · filed 2021-03-17 | |
| 2019-09-30 | $10.65M 10-Q · filed 2020-11-23 | $28.30M 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |